Latest news

• Ex-Pharmacyclics CEO invests $25m in Summit

  After Duchenne drug failure, UK biotech looks to new anti-infective. US biotech billionaire Bob Duggan is to invest $25m into antibiotics developer Summit Therapeutics, taking a near-49% stake in ... At the time, Summit said that would be enough for the

• Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

  News from pharma, biotech and healthcare. Summit gets $12m lifeline for C diff drug. ... UK specialist pharma company Summit Therapeutics has been awarded an extra $12m from a US government department to fund development of a new antibiotic.

• Mallinckrodt doses first patient in muscular dystrophy trial

  Mallinckrodt’s step forward comes shortly after another UK biotech, Summit Therapeutics, saw its shares go into freefall in June after its DMD candidate ezutromid failed a phase II trial.

• Summit plunges after Duchenne disappointment

  Shares in UK biotech Summit Therapeutics plunged 80% after its treatment for Duchenne muscular dystrophy (DMD) failed in phase II trials. ... trials. "These data come as a great disappointment to us and to all those living with DMD," said Glyn Edwards,

• BioMarin files muscular dystrophy drug in EU

  restored. It is suitable for treating around 13% of DMD cases. At the moment the only approved therapy for DMD in Europe is PTC Therapeutics' small-molecule drug Translarna (ataluren), which ... UK-based Summit Therapeutics has also entered the race